GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hebei Changshan Biochemical Pharmaceutical Co Ltd (SZSE:300255) » Definitions » Capex-to-Operating-Cash-Flow

Hebei Changshan Biochemical Pharmaceutical Co (SZSE:300255) Capex-to-Operating-Cash-Flow : 0.28 (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Hebei Changshan Biochemical Pharmaceutical Co Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Hebei Changshan Biochemical Pharmaceutical Co's Capital Expenditure for the three months ended in Mar. 2025 was ¥-28.94 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2025 was ¥102.99 Mil.

Hence, Hebei Changshan Biochemical Pharmaceutical Co's Capex-to-Operating-Cash-Flow for the three months ended in Mar. 2025 was 0.28.


Hebei Changshan Biochemical Pharmaceutical Co Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Hebei Changshan Biochemical Pharmaceutical Co's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hebei Changshan Biochemical Pharmaceutical Co Capex-to-Operating-Cash-Flow Chart

Hebei Changshan Biochemical Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 107.31 137.95 7.10 4.26

Hebei Changshan Biochemical Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.52 - - 0.28

Competitive Comparison of Hebei Changshan Biochemical Pharmaceutical Co's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Hebei Changshan Biochemical Pharmaceutical Co's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hebei Changshan Biochemical Pharmaceutical Co's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hebei Changshan Biochemical Pharmaceutical Co's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Hebei Changshan Biochemical Pharmaceutical Co's Capex-to-Operating-Cash-Flow falls into.


;
;

Hebei Changshan Biochemical Pharmaceutical Co Capex-to-Operating-Cash-Flow Calculation

Hebei Changshan Biochemical Pharmaceutical Co's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-239.591) / 56.218
=4.26

Hebei Changshan Biochemical Pharmaceutical Co's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-28.937) / 102.992
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hebei Changshan Biochemical Pharmaceutical Co  (SZSE:300255) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Hebei Changshan Biochemical Pharmaceutical Co Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Hebei Changshan Biochemical Pharmaceutical Co's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Hebei Changshan Biochemical Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
North of Yinchuan Street, Zhengding New District, Hebei, Shijiazhuang, CHN, 050800
Hebei Changshan Biochemical Pharmaceutical Co Ltd is a biotech high-tech enterprise. It is mainly engaged in the research, development, production, and sale of heparin series products. Some of the company's products are Reserpine sodium, Hyaluronic acid, Heparinoid, Heparin sodium, Tinzaparin sodium, Aspirin enteric-coated tablets, and Yihaitang.
Executives
Li Zhi Hua Executives
Wang Jun Executives
Ding Jian Wen Directors, executives
Huang Guo Sheng Executives
Gao Shu Hua Directors, executives
Chen Xi Director
Cai Hao Executives
Ji Sheng Li Directors, executives
Li Xin Securities Affairs Representative
Zhang Wei Secretary Dong
Liu Jian Executives
Zhang Zhi Ying Executives
Guo Yan Xing Supervisors

Hebei Changshan Biochemical Pharmaceutical Co Headlines

No Headlines